Amerika Serikat - Inggris - NLM (National Library of Medicine)

virbac ah, inc - ivermectin (unii: 8883yp2r6d) (ivermectin - unii:8883yp2r6d), pyrantel pamoate (unii: 81bk194z5m) (pyrantel - unii:4qih0n49e7) - indications: for use in dogs to prevent canine heartworm disease by eliminating the tissue stage of heartworm larvae (dirofilaria immitis) for a month (30 days) after infection and for the treatment and control of roundworms (toxocara canis, toxascaris leonina) and hookworms (ancylostoma caninum, uncinaria stenocephala, ancylostoma braziliense).

Amerika Serikat - Inggris - NLM (National Library of Medicine)

h2-pharma llc - olanzapine pamoate (unii: x7s6q4mhcb) (olanzapine - unii:n7u69t4szr) - zyprexa relprevv is available only through a restricted distribution program [see warnings and precautions (5.2)] . zyprexa relprevv must not be dispensed directly to a patient. for a patient to receive treatment, the prescriber, healthcare facility, patient, and pharmacy must all be enrolled in the zyprexa relprevv patient care program. to enroll, call 1-877-772-9390. zyprexa relprevv is indicated for the treatment of schizophrenia. efficacy was established in two clinical trials in patients with schizophrenia: one 8-week trial in adults and one maintenance trial in adults [see clinical studies (14.1)] . none. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including zyprexa relprevv, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-prog

Amerika Serikat - Inggris - NLM (National Library of Medicine)

winder laboratories, llc - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - for once daily self-applied systemic use as a dental caries preventive in pediatric patients. it has been established that ingestion of fluoridated drinking water (1 ppm f¯) during the period of tooth development results in a significant decrease in the incidence of dental caries. sodium fluoride chewable tablets were developed to provide systemic fluoride for use as a supplement in pediatric patients from age 3 years to age 16 years and older living in areas where the drinking water fluoride contents does not exceed 0.6 ppm f¯. fluoride 1.0 mg tablets are contraindicated when the fluoride content of drinking water is >0.3 ppm f¯ and should not be administered to pediatric patients under 6 years. fluoride 0.5 mg tablets are contraindicated when the fluoride content of drinking water is more than 0.6 ppm f¯ and should not be administered to pediatric patients under age 6 when the fluoride content of drinking water is 0.3 ppm f¯ or more or to pediatric patients under age 3 years. fluoride 0.25 mg tablets are contraindicated when the fluoride content of drinking water is more than 0.6 ppm f¯ and should not be administered to pediatric patients under age 3 years when the fluoride content of drinking water is 0.3 ppm f¯ or more. do not administer sodium fluoride chewable tablets (any strength) to pediatric patients under age 3 years. sodium fluoride chewable tablets (any strength) are not indicated for use in adults.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

glaxosmithkline llc - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 3.125 mg - coreg is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ace inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see drug interactions (7.4), clinical studies (14.1)] . coreg is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see clinical studies (14.2)] . coreg is indicated for the management of essential hypertension [see clinical studies (14.3, 14.4)] . it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2)] . coreg is contraindicated in the following conditions: risk summary available data regarding use of coreg in pregnant women are insufficient to determine whether there are drug-

Amerika Serikat - Inggris - NLM (National Library of Medicine)

woodward pharma services llc - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - coreg is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ace inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see drug interactions (7.4), clinical studies (14.1)]. coreg is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see clinical studies (14.2)]. coreg is indicated for the management of essential hypertension [see clinical studies (14.3, 14.4)]. it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2)]. coreg is contraindicated in the following conditions: - bronchial asthma or related bronchospastic conditions. deaths from status asthmaticus have been reported following single d

Amerika Serikat - Inggris - NLM (National Library of Medicine)

glaxosmithkline llc - fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - fluticasone propionate 44 ug - flovent hfa is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients aged 4 years and older. limitations of use flovent hfa is not indicated for the relief of acute bronchospasm. flovent hfa is contraindicated in the following conditions: risk summary there are insufficient data on the use of flovent hfa in pregnant women. there are clinical considerations with the use of flovent hfa in pregnant women. (see clinical considerations.) in animals, teratogenicity characteristic of corticosteroids, decreased fetal body weight and/or skeletal variations in rats, mice, and rabbits, was observed with subcutaneously administered maternal toxic doses of fluticasone propionate less than the maximum recommended human daily inhaled dose (mrhdid) on a mcg/m2 basis. (see data.) however, fluticasone propionate administered via inhalation to rats decreased fetal body weight but did not induce teratogenicity at a maternal toxic dose less than the mrhdid on a mcg/m2 basis.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

mylan institutional inc. - venlafaxine hydrochloride (unii: 7d7rx5a8mo) (venlafaxine - unii:grz5rcb1qg) - venlafaxine 37.5 mg - venlafaxine tablets, usp are indicated for the treatment of major depressive disorder. the efficacy of venlafaxine tablets in the treatment of major depressive disorder was established in 6-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the dsm-iii or dsm-iii-r category of major depression and in a 4-week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see clinical trials). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least four of the following eight symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suic

Amerika Serikat - Inggris - NLM (National Library of Medicine)

mylan institutional inc. - fluvoxamine maleate (unii: 5lgn83g74v) (fluvoxamine - unii:o4l1xpo44w) - fluvoxamine maleate 50 mg - fluvoxamine maleate tablets are indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (ocd), as defined in dsm-iii-r or dsm-iv. the obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. obsessive compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. the efficacy of fluvoxamine maleate tablets was established in four trials in outpatients with ocd: two 10-week trials in adults, one 10-week trial in pediatric patients (ages 8 to 17), and one maintenance trial in adults [see clinical studies (14)]. [see warnings and precautions (5.4 to 5.7).] the use of maois intended to treat psychiatric disorders with fluvoxamine maleate tablets or w

Amerika Serikat - Inggris - NLM (National Library of Medicine)

pharmaceutical associates, inc. - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - attention deficit disorders (previously known as minimal brain dysfunction in children). other terms being used to describe the behavioral syndrome below include: hyperkinetic child syndrome, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction. methylphenidate hydrochloride oral solution is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be wa

Amerika Serikat - Inggris - NLM (National Library of Medicine)

shiseido americas corporation - titanium dioxide 1.6% - sunscreen - helps prevent sunburn - if used as directed with other sun protection measures (see directions ), decreases the risk of skin cancer and early skin aging caused by the sun